Abstract Submission - APHIA 2025 - Asia-Pacific Histocompatibility and Immunogenetics Association

e-Poster Timeslot

Abstract ID	Session	Abstract Title	Presenting Author
APHIA-004	Autoimmunity and Tumour Immunology	Tumor cells acquire CTL resistance	Prof. Hun Mo Ryoo, Daegu Catholic Univ Medical Center/Oncology, Korea
APHIA-038	Autoimmunity and Tumour Immunology	IMMUNOSUPPRESSIVE MICROENVIRONMENT IN TRIPLE-NEGATIVE BREAST CANCER WITH HIGH TUMOR BUDDING	Dr. Suparada Khanaruksombat, Siriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
APHIA-030	Immunotherapy	Evaluation of B7-H3 CAR T cells with Distinct Co-stimulation Strategies in Cholangiocarcinoma	Ms. Atittaya Wakwatanyoo, Pharmaceutical Sciences and Technology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
APHIA-029		Antitumor Activities of Chimeric Antigen Receptor T Cells Targeting Mucin-1 with Self-secreting Anti PD-1 IgG Antibody	Ms. Nattarika Khuisangeam, Chulalongkorn university, Thailand
APHIA-010		Bi-direct promoter for anti-PD1/CD19 CAR	Dr. Asmita Khaniya, Faculty if Medicine, Chulalongkorn University, Thailand
APHIA-025		Targeting CD117 with mRNA-based CAR T cells approached high activity against AML with less long-term toxicity to normal hematopoietic stem cells (HSCs)	Ms. Thananya Inthanachai, Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand
APHIA-028		Development of an off-the-shelf allogeneic engineered immune cell for cancer therapy	Ms. Proudphat Jumnongjit, Chulalongkorn University, Thailand
APHIA-031		Off-the-shelf CAR T cells production using CRISPR/Cas9 and mRNA technologies	Ms. Thanyaporn Buakaew, Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
APHIA-032		Generation of chimeric antigen receptor T-cell targeting folate receptor-α from human heavy chain-only antibody	Dr. Nithidol Sakunrangsit, Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand; Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand
APHIA-007		Advanced CAR T Cells for CD19 and BCMA	Mr. Siwakorn Sangsawang, Medical microbiology, Interdisciplinary program, Graduated school, Chulalongkorn University, Thailand
APHIA-008		Anti-GD2xCD3 Engager For Lung Cancer	Assoc. Prof. Aussara Panya, Cell Engineering for Cancer Therapy Research Group, Chiang Mai University, Thailand
APHIA-044		Comparing the Clinical Outcomes among Three Chimeric Antigen Receptor T (CAR-T) Cell Therapies (Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel) for Lymphoma Patients: A Bayesian Network Meta-Analysis	I Gede Wikania Wira Wiguna, Udayana University, Indonesia

Abstract ID	Session	Abstract Title	Presenting Author
APHIA-026	Haematopoietic Stem Cell Transplantation (HSCT)	Bridging the Cryopreservation Gap: Validated Protocol for 5-Day Stem Cell Storage at 4°C	Ms. SIRILUK CHEUNTA, Blood Transfusion Center, Faculty of Medicine, Khon Kaen University, Thailand
APHIA-001		Using HaploStats to predict HLA genotype	PhD, Dr. Elena Kuzmich, Russian Research Institute of Hematology and Transfusiology, Russia
APHIA-006		HLA-A, -B, -C, -DRB1, -DQB1 homozygous Russian volunteer stem cell donors	Dr. Ekaterina Khamaganova, National Medical Research Center for Hematology, Russia
APHIA-040	Technologies and Cutting-edge Scientific Developments	Flow Cytometric Chimerism Assay For Haploidentical Stem Cell Transplantation Monitoring	Mr. Kam Ying Tong, Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong
APHIA-002	Technologies and Cutting-edge Scientific Developments	FASTASeq 300 aplication for HLA typing	Mrs. Irina Pavlova, Russian Research Institute of Hematology and Transfusiology, Russia
APHIA-024	Laboratory Quality	Analysis of Stem Cell Collection Efficiency and Benchmark Establishment at Khon Kaen University	Ms. Seesuda Prathummes, Blood Transfusion Center, Faculty of Medicine, Khon Kaen University, Thailand
APHIA-039	Population Genetics	Killer cell Immunoglobulin-like Receptors (KIR) gene and haplotype frequencies in Hong Kong Population	Dr. Stephen Cheung, Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong
APHIA-017		Novel HLA-A, -B, -C and -DRB1 alleles id	Dr. Marija Velickovic, New South Wales Transplantation and Immunogenetics Services Pathology and Clinical Governance, Australian Red Cross Lifeblood, Sydney, Australia
APHIA-035		HLA-DRB1*13:363, a new allele discovered by Next Generation Sequencing in stem cell volunteer donors by National Blood Centre, Thai Red Cross Society.	Ms. Mookmanee Vesadapun, National Blood Centre, Thai Red Cross Society, Thailand
APHIA-014		HLA-B Allele Frequencies in Idiopathic Uveitis Patients from Northern Thailand: A Nanopore Sequencing study	Mr. Auttachai Saejia, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai and Siriraj Long-read Lab (Si-LoL), Division of Medical Bioinformatics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
APHIA-042		HLA and Disease Association: A Comprehensive Review and Subtype Frequency Analysis in a Hospital Setting	Mr. Poonlaph Phaingchomduan, King Chulalongkorn Memorial Hospital, Thailand

Abstract ID	Session	Abstract Title	Presenting Author
APHIA-012	Biomarker	Anti-HLA Class I and Preterm Delivery	Ms. Sirikul Laosrivichit, Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand
APHIA-027	HLA antibody detection	Prediction of High Panel Reactive Antibody (PRA) Levels Using LabscreenTM Mixed screening test Parameters.	Ms. Yupaporn Sudwilai, Blood transfusion center, Faculty of Medicine, Khon Kaen University, Thailand
APHIA-033	Solid Organ Transplantation	Results of final lymphocyte crossmatching for living related kidney transplantation: experience from tertiary care hospital, Bangkok, Thailand	Assoc. Prof. Parichart Permpikul, Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
APHIA-018		Non-HLA antibodies in Lung Transplants	Mr. Steven Hiho, Australian Redcross Lifeblood, Australia
APHIA-021		Case study: Comprehensive investigation of false bead reactivity permits living directed donor kidney transplantation	Ms. Hannah Sullivan, South Australian Transplantation and Immunogenetics Service, Australian Red Cross Lifeblood, Australia
APHIA-016		HLA and non-HLA Ab post Liver/Kidney Tx	Mr. Tim Emery, Australian Red Cross Lifeblood – SATIS, Australia
APHIA-019		Insights from APHIA Virtual Challenge	Ms. Eleni Tsiopelas, South Australian Transplantation & Immunogenetics Service, Australian Red Cross Lifeblood, Australia

Abstract Submission Guideline

Important Dates to Know

Deadline for Abstract Submission

October 15, 2024 (Extend to October 25, 2024)

Abstract Announcement

October 31, 2024 (Extend to November 5, 2024)

Deadline for Early Bird Registration

November 20, 2024

How to Submit the Abstract

Create an account: If you haven’t already, create an account on our submission portal to access the abstract submission form.
Prepare your abstract: Write your abstract according to the provided guidelines, ensuring clarity, conciseness, and scientific rigor.
Submit your abstract: Log in with your APHIA 2025 credentials to submit your application. Complete the online abstract application by the appropriate deadline.
Review and confirmation: After submission, you will receive a confirmation email acknowledging receipt of your abstract. You will also be notified of the review outcome in due course.

Submission Guidelines

Abstract submissions are open to all professionals, including researchers, residents, fellows, and allied health professionals.
Each abstract should adhere to the specified formatting guidelines and include essential components such as background, methods, results, and conclusions.
Abstracts will undergo peer review by a panel of experts in the field.
Accepted abstracts will be scheduled for an oral or an ePoster presentation at the APHIA 2025.

Instructions to Complete Abstract Application

Title
- The title is limited to 40 characters (including punctuation, but not spaces) and must begin with a capital letter and be followed by lowercase letters.
- Do not include any abbreviations in the title.
Abstract:
- Length: Do not exceed the space provided on the application (500 words)
- Language: Use English only
- The abstract must include four parts:
  1. Background should clearly state the problem and the purpose of the study.
  2. Methods should provide a description of what was actually done.
  3. Results should contain the study findings.
  4. Discussion and conclusion should be based on the findings and relate to the stated purpose of the study and existing knowledge.
- DO NOT use abbreviations that have not been specified first.
- List all authors in the space provided.
- Authors may not be added or removed after submission closes on October 15, 2024 (Extend to October 25, 2024), nor after acceptance.